Longevity Tech

The quest to live better for longer

Overview

Longevity technology (tech) refers to the development of various methods that allow humans to measure, track, and potentially modify the physiological changes associated with aging. The 21st century saw a significant increase in research activity, making space for the emergence of a commercial longevity tech industry enabled by technological advancements. Recent developments, such as AI and blockchain technologies, are being used across the spectrum of longevity research. Their ability to process large datasets and derive intelligent patterns has astronomically changed the parameters of what is possible within the industry. Previously only accessible to the affluent and privileged, the longevity space now has the potential to reach the general population and disrupt the healthcare sector. 

The longevity tech market is driven by two key factors. First, the US is experiencing a significant demographic shift, with its aging population expanding. This demographic transformation is creating a pressing need for innovative solutions that can enhance the quality of life and well-being of older adults. Concurrently, there is a palpable surge in tech-enabled longevity research, fostering innovations that are increasingly accessible to the broader public.

Industry Updates

View all updatesicon
Market Sizing

The US Longevity Tech market could reach USD 5.0 billion–6.9 billion by 2028

Conservative case

USD 0.0 Bn

Base case

USD 0.0 Bn

Expansion case

USD 0.0 Bn

Market Mapping


The market can be broadly segmented into seven based on the type of solution. Most disruptors are focused on developing longevity-focused cell and gene therapies; this segment also accounts for the largest amount of funding across the industry.

Major global healthcare giants such as Roche, Bayer, and Novartis are among the incumbents active in this space, with partnerships and product collaborations being the most common growth strategy adopted by these players, along with some large acquisitions to accelerate the product portfolio.

The Disruptors


Most disruptors in longevity tech, particularly in the longevity-focused cell and gene therapy segment, are at the seed/pre-seed stage, despite having raised several hundred million dollars in funding and nearly 80% of all companies having been founded in the last decade, indicating the significant financial and time investment required to move therapies from the research/testing stage to market.

Altos Labs—a startup reportedly backed by Jeff Bezos—was by far the most funded company in the space, launching in 2022 with USD 3 billion in funding to explore cellular rejuvenation.

Funding History

Competitive Analysis


Filter by a segment or companies of your choice
expand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

Incumbents


Major global pharmaceutical giants such as Roche, Bayer, and Novartis are among the incumbents active in longevity tech, with a greater focus on longevity-focused cell and gene therapies and therapies for sensory loss. Big Tech companies such as Apple and Alphabet have a presence in diagnostics and lifestyles through their wearable devices such as the Apple Watch and Fitbit. The most common growth strategy for incumbents has been partnerships and product collaborations with startups and other incumbents.

Roche’s acquisition of Genentech more than a decade ago for ~USD 46.8 billion remains the largest longevity tech acquisition to date. The largest recent deals were Alphabet’s acquisition of Fitbit for ~USD 2.1 billion in 2021, followed by Novartis’ acquisition of Gyroscope Therapeutics for ~USD 1.5 billion in 2021 to expand its presence in sensory loss therapies.

In House Development
M&A
Partnership
Investment
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

Notable Investors


?
Funding data are powered by Crunchbase
arrow
menuarrow
close

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo

Overview

Longevity tech focuses on extending lifespan and healthspan through innovative solutions

Longevity tech has been defined as the development of various methods that allow humans to measure, track, and potentially modify the physiological changes associated with aging. The goal of longevity tech is to extend not only human lifespan but also healthspan—the period of life spent in good health and free from chronic diseases that typically accompany aging. This distinguishes it from anti-aging solutions, which usually refer to cosmetic treatments and procedures to mitigate the effects of aging.

How does Longevity Tech work?

Longevity tech is linked to geroscience, which is the study of aging processes and how they drive chronic diseases, to develop interventions that extend human healthspan and prevent age-related diseases. Although the human body begins to physically decline at around age 30, longevity studies distinguish between chronological age and biological age. Chronological age is our age in calendar years and may differ from our biological age, which is our body’s internal age. Biological age is considered a better indicator of aging because it reflects the effects of genetics and lifestyle factors, such as diet, exercise, stress, and sleep. Accordingly, different organs can have different biological ages, and these biological ages can be accelerated or slowed.
The three main targets of longevity tech are considered to be 1) longevity determinants, namely, genetics, environment, and lifestyle; 2) molecular drivers of aging that include the “nine hallmarks of aging” introduced in 2013; and 3) diseases that are strongly associated with aging. Consequently, longevity tech companies are organized around these targets, developing solutions that focus on one or more of the four “pillars” of longevity intervention:
  1. Identifying health status and early detection of age-related damage (diagnostics)
  2. Preventing or delaying the damage that causes aging (prevention)
  3. Treating the damage caused by aging (treatment)
  4. Reversing the damage that has occurred (renewal)
Longevity tech targets and interventions
Molecular drivers include the “nine hallmarks of aging” which were introduced by Professor Carlos López-Otín in 2013
Source: Compiled by SPEEDA Edge based on information presented by Longevity.Technology
Longevity tech industry focus areas
A loose categorization of focus areas which may span more than one longevity tech target
Source: Compiled by SPEEDA Edge based on the 25 market domains presented by Longevity.Technology
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.